Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection

No abstract is available for this paper.

• Publication year

  2000

• Venue

  AIDS (London)

• Publication date

  2000-12-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00002030-200012220-00001PMID 11153661
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A CONTROLLED TRIAL OF TWO NUCLEOSIDE ANALOGUES PLUS INDINAVIR IN PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND CD4 CELL COUNTS OF 200 PER CUBIC MILLIMETER OR LESS

  2000cited by this paper
• Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia

  2000cited by this paper
• The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy

  2000cited by this paper
• The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.

  1999cited by this paper
• HIV-1 replication in patients with undetectable plasma virus receiving HAART

  1999cited by this paper
• HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy.

  1999cited by this paper
• Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.

  1999cited by this paper
• Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy

  1999cited by this paper
• Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.

  1999cited by this paper
• Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy

  1999cited by this paper
• Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

  1999cited by this paper
• Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia.

  1999cited by this paper
• Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

  1999influential reference
• Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

  1999cited by this paper
• Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy.

  1998cited by this paper
• Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

  1997cited by this paper
• Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

  1997cited by this paper
• Detection of low HIV-1 RNA levels in plasma.

  1997cited by this paper
• Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

  1997cited by this paper
• A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

  1997cited by this paper
• Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

  1997cited by this paper
• HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time

  1996cited by this paper
• In vivo estimates of division and death rates of human T lymphocytes.

  1995cited by this paper
• Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

  1995cited by this paper
• HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

  1990cited by this paper
• The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4.

  1989cited by this paper

• Longitudinal changes in the transcriptionally active and intact HIV reservoir after starting ART during acute infection

  2025cites this paper
• Acute HIV-1 Infection: Paradigm and Singularity

  2025cites this paper
• Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPL’HIV Trial)

  2022cites this paper
• Qualitative plasma viral load determination as a tool for screening of viral reservoir size in PWH

  2022cites this paper
• Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study

  2021cites this paper
• Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy

  2021cites this paper
• HIV-1 variants are archived throughout infection and persist in the reservoir

  2020cites this paper
• Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.

  2019cites this paper
• Sexual dimorphism in HIV-1 infection

  2018cites this paper
• What do we measure when we measure cell-associated HIV RNA

  2018cites this paper
• Total HIV-1 DNA Dynamics and Influencing Factors in Long-Term ART-Treated Japanese Adults: A Retrospective Longitudinal Analysis

  2018cites this paper
• Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand

  2017cites this paper
• Combination antiretroviral therapy and cell–cell spread of wild-type and drug-resistant human immunodeficiency virus-1

  2017cites this paper
• Barriers to a cure for HIV in women

  2016cites this paper
• Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications

  2016cites this paper
• Impact of Antiretroviral Therapy on HIV-1 Persistence: The Case for Early Initiation.

  2015cites this paper
• Prise en charge de la primo-infection VIH-1

  2015cites this paper
• Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes

  2015cites this paper
• Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.

  2015cites this paper
• HIV-1 Non-R 5 Co-receptor Tropism is Associated with a Larger Size of the Viral Reservoir but not with a Higher Risk of Virological Rebound in Patients on Effective Antiretroviral Therapy

  2015cites this paper
• Etude de l’établissement des réservoirs VIH lors de la primo-infection et de l’impact des traitements antirétroviraux très précoces sur ces réservoirs

  2014cites this paper
• Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy

  2014cites this paper
• The Use of Ultra-Sensitive Molecular Assays in HIV Cure-Related Research

  2013cites this paper
• HIV-1 transcription and latency: an update

  2013cites this paper
• Cell-associated HIV RNA: a dynamic biomarker of viral persistence

  2013cites this paper
• Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)

  2013cites this paper
• A Symmetric Region of the HIV-1 Integrase Dimerization Interface Is Essential for Viral Replication

  2012cites this paper
• Combination Therapy of AIDS

  2012cites this paper
• Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy

  2012cites this paper
• New Tools for Quantifying HIV-1 Reservoirs: Plasma RNA Single Copy Assays and Beyond

  2012cites this paper
• CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs

  2011cites this paper
• Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly Active Antiretroviral Therapy

  2011cites this paper
• Randomized controlled stu dy demonstrating failure of LPV / r monotherapy in HIV : the role of compartment and CD 4-nadir

  2010cites this paper
• Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir

  2010cites this paper
• Immunomagnetic quantitative immuno-PCR for detection of less than one HIV-1 virion.

  2009influential citation
• Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome

  2009cites this paper
• L'ADN VIH-1: évolution au cours de l'infection, valeur pronostique et intérêt

  2009cites this paper
• Overestimation of Human Immunodeficiency Virus Type 1 Load Caused by the Presence of Cells in Plasma from Plasma Preparation Tubes (cid:1)

  2009influential citation
• Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.

  2009cites this paper
• Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

  2009cites this paper
• Overestimation of Human Immunodeficiency Virus Type 1 Load Caused by the Presence of Cells in Plasma from Plasma Preparation Tubes

  2009influential citation
• Cytokine Expression in the Colonic Mucosa of Human Immunodeficiency Virus-Infected Individuals before and during 9 Months of Antiretroviral Therapy

  2008cites this paper
• HIV-1-infected CD8+CD4+ T cells decay in vivo at a similar rate to infected CD4 T cells during HAART

  2008cites this paper
• Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.

  2008cites this paper
• HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission

  2008cites this paper
• Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure

  2008cites this paper
• Treatment of acute HIV-1 infection: are we getting there?

  2008cites this paper
• Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.

  2008cites this paper
• HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is.

  2008cites this paper
• Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

  2007cites this paper
• Optimal Timing and Duration of Induction Therapy for HIV-1 Infection

  2007cites this paper
• Primäre HIV-1-Infektion : Virologische und immunologische Korrelate einer endogenen Kontrolle der Virusreplikation

  2007cites this paper
• Herstellung und Evaluierung transdominant negativ wirksamer Varianten des HIV-1 gruppenspezifischen Antigens als Basiskomponente einer HIV-1-Gentherapie

  2006cites this paper
• Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy.

  2006cites this paper
• HIV-1-Specific CD4+ T Cell Responses in Chronically HIV-1 Infected Blippers on Antiretroviral Therapy in Relation to Viral Replication Following Treatment Interruption

  2006cites this paper
• Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.

  2005cites this paper
• Basics of the virology of HIV-1 and its replication.

  2005cites this paper
• Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.

  2005cites this paper
• Contribution of Cellular HIV-1 DNA Quantification to the Efficacy Analysis of Antiretroviral Therapy: A Randomized Comparison of 2 Regimens, Including 3 Drugs From 2 or 3 Classes (TRIANON, ANRS 081)

  2005cites this paper
• Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue

  2005cites this paper
• Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/µl? Impact on immunovirological parameters

  2005cites this paper
• Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions

  2005cites this paper
• New estimation method for highly sensitive quantitation of human immunodeficiency virus type 1 DNA and its application.

  2005cites this paper
• Relationship between Changes in Thymic Emigrants and Cell-Associated HIV-1 Dna in HIV-1-Infected Children Initiating Antiretroviral Therapy

  2005cites this paper
• British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008

  2005cites this paper
• Association between Cellular Human Immunodeficiency Virus DNA Level and Immunological Parameters in Patients with Undetectable Plasma Viremia Level during Highly Active Antiretroviral Therapy

  2005cites this paper
• Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

  2005cites this paper
• Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection

  2004cites this paper
• Highly active antiretroviral treatment (HAART) of pediatric HIV-1 infection

  2004cites this paper
• Primary HIV infection: from diagnosis to treatment

  2004cites this paper
• Persistent HIV Type 1 Infection in Semen and Blood Compartments in Patients after Long-Term Potent Antiretroviral Therapy

  2004cites this paper
• Understanding HIV-1 drug resistance.

  2004cites this paper
• Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

  2004cites this paper
• HIV Type 1 DNA Development during Long-Term Supervised Therapy Interruption

  2003cites this paper
• Tenofovir Disoproxil Fumarate

  2003cites this paper
• Viral Blip Dynamics during Highly Active Antiretroviral Therapy

  2003cites this paper
• Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy

  2003cites this paper
• HIV therapies : From Health-related quality of life to DNA levels

  2003cites this paper
• The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy

  2003cites this paper
• Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level

  2003cites this paper
• Surrogate markers as a guide to evaluate response to antiretroviral therapy.

  2003cites this paper
• Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.

  2003cites this paper
• HIV-1 reservoirs.

  2002cites this paper
• Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?

  2002cites this paper
• Cell-associated HIV DNA Measured Early During Infection has Prognostic Value Independent of Serum HIV RNA Measured Concomitantly

  2002cites this paper
• Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4<200 Cells/Mm3) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial)

  2002cites this paper
• Addition of Cyclophosphamide to Antiretroviral Therapy Does Not Diminish the Cellular Reservoir in HIV-Infected Persons

  2002cites this paper
• Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

  2002cites this paper
• Therapeutic vaccination in primary HIV infection, the Quest trial.

  2002cites this paper
• HIV-1 infection and low steady state viral loads

  2002cites this paper
• Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14+ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy

  2002cites this paper
• Brief Report: Efficacy and Safety of a Quadruple Combination Combivir + Abacavir + Efavirenz Regimen in Antiretroviral Treatment‐Naive HIV‐1‐Infected Adults: La Francilienne

  2002cites this paper
• Primo-infection VIH : revue de la littérature et suivi à 5 ans de 15 patients sous bithérapie

  2002cites this paper
• Residual Viral Replication during Antiretroviral Therapy Boosts Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses in Subjects Treated Early after Infection

  2002cites this paper
• A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.

  2002cites this paper
• Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.

  2002cites this paper
• Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.

  2002cites this paper
• Evaluation of PCR-based methods for the quantitation of integrated HIV-1 DNA.

  2002cites this paper
• Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.

  2002influential citation
• Decay of HIV Type 1 DNA and Development of Drug-Resistant Mutants in Patients with Primary HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy

  2001cites this paper